Boehringer Ingelheim struck an agreement with the U.S. administration to join a government-run purchasing platform and pledged up to $10 billion in U.S. investments through 2028 to expand manufacturing and R&D. The company’s commitment included tariff protections and participation in a direct-purchase portal intended to lower medicine costs for American patients. Separately, Boehringer announced a strategic research and licensing deal with Rectify Pharmaceuticals to accelerate oral therapies for chronic kidney disease, a collaboration valued at up to $448 million in milestones. The partnership pairs Boehringer’s scale and commercial reach with Rectify’s preclinical kidney-focused program. These moves show a dual approach: public-facing pricing concessions with sustained industrial investment, and targeted R&D tie-ups to replenish mid- and late-stage pipelines in cardiometabolic and renal disease.